Sleuth Studio

The deliverable, and the data to defend it

Tell Sleuth what you’re deciding. It works through every program, deal, and document, then builds the interactive analysis, deck, or spreadsheet, with a source on every number.

Set up in Claude, ChatGPT, or Copilot

A Sleuth deck slide, Pitch these four first, with the partner map and one line per partner

Click through it, present it, or open it in Excel

Sleuth builds what the question calls for: a partner map you can click through, slides for the meeting, or every row in a spreadsheet, all from the same knowledge base. Every number can be traced to its source, and you can hand the whole project to Claude or your team.

Interactive analysis

Click any company or program to see its row and its sources.

Deck

Slides for the meeting, built from the same rows.

Spreadsheet

Every row, plus the working data behind the analysis.

One of our own projects, three ways: our Q3 deep dive on T-cell engagers.

Explore

Everything Sleuth reads, you can explore too

Every plan includes the knowledge base and documents Sleuth works from, so you don’t need a separate database or document search seat. Unlimited searching and exploring on all plans.

An explorable knowledge base

Everything your database has, connected. Browse and filter drugs, trials, deals, companies, and targets, the same records Sleuth uses. Browsing them is unlimited. Credits are used when Sleuth builds analysis on top.

Searchable documents

Search 150M+ documents, including sell-side research from 35+ providers, filings, press releases, and conference abstracts, then read any of them in full. Upload your own files, and Sleuth reads those too.

Analyze

Give Sleuth the whole project

Ask in your own words, or start from a workflow. Either way, Sleuth plans the project, builds the datasets, reads the filings and earnings calls, and checks its own work before it builds the deliverable.

Ask in your own words

Type the decision you’re making. Sleuth answers with a plan you can edit, approve, or run straight through with auto-approve.

Built on your criteria, with the data your question needs

Sleuth starts from the fields every database has, then adds the data needed to answer your question. It reads abstracts, posters, filings, and earnings calls to fill it in, with a source on every value.

“We’re a biotech building a solid-tumor T-cell engager, and we need to know where the modality is heading. Which engineering choices have produced credible clinical signals in solid tumors, and what do they imply?”

Standard database columnsColumns Sleuth builds for you
CompanyAssetTargetStageDetailed mechanismSynapse engineeringReference clinical readoutStrategic read-through
AmgenTarlatamab (Imdelltra)DLL3 × CD3Approved in the USHalf-life-extended 1+1 BiTESignal 1 onlyOS 13.6 vs 8.3 monthsA conventional architecture can work when the tumor antigen is lineage-restricted and target density is favorable, so target choice can matter more than architectural novelty.
Zelgen / AbbVie optionAlveltamig (ZG006)DLL3 × DLL3 × CD3Phase 3 in ChinaTrispecific, two epitopesSignal 1 plus biparatopicORR 53 to 57%Fast followers are competing on epitope geometry and avidity around validated targets, and the ex-Greater China option shows the design difference is transaction-relevant.
Vir / AstellasVIR-5500 (AMX-500)PSMA × CD3Phase 1 dose expansionDual-masked PRO-XTENSignal 1 plus conditionalPSA50 82%, ORR 45%Masking is becoming a practical route to dose intensity for targets expressed on normal tissue, and the collaboration carried $335M upfront and near-term plus up to $1.37B in further milestones.

Columns Sleuth builds for you

Amgen

AssetTarlatamab (Imdelltra)

TargetDLL3 × CD3

StageApproved in the US

Detailed mechanismHalf-life-extended 1+1 BiTE

Synapse engineeringSignal 1 only

Reference clinical readoutOS 13.6 vs 8.3 months

Strategic read-throughA conventional architecture can work when the tumor antigen is lineage-restricted and target density is favorable, so target choice can matter more than architectural novelty.

Zelgen / AbbVie option

AssetAlveltamig (ZG006)

TargetDLL3 × DLL3 × CD3

StagePhase 3 in China

Detailed mechanismTrispecific, two epitopes

Synapse engineeringSignal 1 plus biparatopic

Reference clinical readoutORR 53 to 57%

Strategic read-throughFast followers are competing on epitope geometry and avidity around validated targets, and the ex-Greater China option shows the design difference is transaction-relevant.

Vir / Astellas

AssetVIR-5500 (AMX-500)

TargetPSMA × CD3

StagePhase 1 dose expansion

Detailed mechanismDual-masked PRO-XTEN

Synapse engineeringSignal 1 plus conditional

Reference clinical readoutPSA50 82%, ORR 45%

Strategic read-throughMasking is becoming a practical route to dose intensity for targets expressed on normal tissue, and the collaboration carried $335M upfront and near-term plus up to $1.37B in further milestones.

“We’re a biotech with a conventional monospecific ADC portfolio, and we want to in-license a differentiated clinical-stage program. Compare how each program is engineered, which limitation it is designed to address, what trade-off that design introduces, and how it would differentiate our portfolio.”

Standard database columnsColumns Sleuth builds for you
CompanyAssetTargetStageDifferentiating designLimitation addressedDesign trade-offPersonalized strategic positioning
DualityBioDB-1419B7-H3 × PD-L1Phase 1/2aBispecific + checkpointImmuno-suppressive TMETwo mechanisms must both landA dual-mechanism ADC for solid tumors where payload delivery alone may be insufficient; expands beyond a conventional monospecific Topo-I ADC portfolio.
Heidelberg PharmaPamlectabart tismanitin (HDP-101)BCMAPhase 2aAmanitin ATACQuiescent tumor cellsUnproven payload classPayload-class diversification within BCMA rather than another conventional ADC using a familiar cytotoxic mechanism.
GileadTUB-040 / GS-8824NaPi2bPhase 1b/2Homogeneous DAR 8High-DAR dosabilityWindow, not just loadingA platform-differentiation play: high drug loading with stability and tolerability as the value proposition, rather than a novel target.

Columns Sleuth builds for you

DualityBio

AssetDB-1419

TargetB7-H3 × PD-L1

StagePhase 1/2a

Differentiating designBispecific + checkpoint

Limitation addressedImmuno-suppressive TME

Design trade-offTwo mechanisms must both land

Personalized strategic positioningA dual-mechanism ADC for solid tumors where payload delivery alone may be insufficient; expands beyond a conventional monospecific Topo-I ADC portfolio.

Heidelberg Pharma

AssetPamlectabart tismanitin (HDP-101)

TargetBCMA

StagePhase 2a

Differentiating designAmanitin ATAC

Limitation addressedQuiescent tumor cells

Design trade-offUnproven payload class

Personalized strategic positioningPayload-class diversification within BCMA rather than another conventional ADC using a familiar cytotoxic mechanism.

Gilead

AssetTUB-040 / GS-8824

TargetNaPi2b

StagePhase 1b/2

Differentiating designHomogeneous DAR 8

Limitation addressedHigh-DAR dosability

Design trade-offWindow, not just loading

Personalized strategic positioningA platform-differentiation play: high drug loading with stability and tolerability as the value proposition, rather than a novel target.

“We’re a biotech with an oral, once-daily TSHR antagonist and can fund one lead indication through proof of concept. Compare Graves disease against both phases of thyroid eye disease, and give us the winnable segment and the fastest proof path for each.”

Standard database columnsColumns Sleuth builds for you
Disease settingUS prevalenceApproved disease-modifying therapiesHighest phaseMechanism-disease fitWinnable patient segmentProof pathIndication priority
Graves disease~900,000NonePhase 3Very highRelapsed or drug-intolerant16-week free T41. Lead. Clearest causal biology and the fastest readout. Price and value have to be built around the high-need subset rather than all Graves patients.
Active moderate-to-severe TED~100,000ThreeApprovedHighCAS ≥3, infusion-averse24-week proptosis2. Expansion. Attractive value pool, but crowding and a higher efficacy bar argue for following Graves proof of mechanism rather than leading here.
Chronic or inactive TEDNot stratifiedThreeApprovedModerate, uncertainPre-surgical persistent24-week proptosis3. Defer. Test after human TSHR proof of mechanism. Do not lead with a fibrosis-heavy population.

Columns Sleuth builds for you

Graves disease

US prevalence~900,000

Approved disease-modifying therapiesNone

Highest phasePhase 3

Mechanism-disease fitVery high

Winnable patient segmentRelapsed or drug-intolerant

Proof path16-week free T4

Indication priority1. Lead. Clearest causal biology and the fastest readout. Price and value have to be built around the high-need subset rather than all Graves patients.

Active moderate-to-severe TED

US prevalence~100,000

Approved disease-modifying therapiesThree

Highest phaseApproved

Mechanism-disease fitHigh

Winnable patient segmentCAS ≥3, infusion-averse

Proof path24-week proptosis

Indication priority2. Expansion. Attractive value pool, but crowding and a higher efficacy bar argue for following Graves proof of mechanism rather than leading here.

Chronic or inactive TED

US prevalenceNot stratified

Approved disease-modifying therapiesThree

Highest phaseApproved

Mechanism-disease fitModerate, uncertain

Winnable patient segmentPre-surgical persistent

Proof path24-week proptosis

Indication priority3. Defer. Test after human TSHR proof of mechanism. Do not lead with a fibrosis-heavy population.

“We’re a biotech preparing a partner process for our oral, once-daily TSHR antagonist in Graves disease, with thyroid eye disease expansion potential. Which pharma companies have the strongest franchise fit, the clearest mechanism whitespace, and an external-innovation history that supports outreach?”

Standard database columnsColumns Sleuth builds for you
PharmaRelevant franchiseClosest relevant assetStage or statusPortfolio provenanceMechanistic whitespaceOverlap riskApproach thesis
AmgenRare inflammatory diseaseTepezza (teprotumumab; IGF-1R)Approved for TEDAcquired: Horizon, $27.8BYes, no TSHR assetHigh in TED, low in GravesTier 1. Lead with a Graves franchise extension and a TED lifecycle option, and define pre- and post-Tepezza segments in the first meeting.
RocheOphthalmology and immunologyEnspryng (satralizumab; IL-6R)Approved for TEDAffiliate: ChugaiYes, no TSHR assetMedium-high in TEDTier 1 to 2. Pitch oral, Graves-first control with TED expansion, and use IL-6R as the downstream comparator rather than the central story.
SanofiRare immune-mediated diseaseRilzabrutinib (BTK)Phase 2 in Graves diseaseAcquired: Principia, $3.68BYes, no TSHR assetHigh in GravesTier 2, conditional. Approach only with compelling TSHR-specific differentiation, biomarker enrichment or a superior safety and response profile. Otherwise deprioritize.

Columns Sleuth builds for you

Amgen

Relevant franchiseRare inflammatory disease

Closest relevant assetTepezza (teprotumumab; IGF-1R)

Stage or statusApproved for TED

Portfolio provenanceAcquired: Horizon, $27.8B

Mechanistic whitespaceYes, no TSHR asset

Overlap riskHigh in TED, low in Graves

Approach thesisTier 1. Lead with a Graves franchise extension and a TED lifecycle option, and define pre- and post-Tepezza segments in the first meeting.

Roche

Relevant franchiseOphthalmology and immunology

Closest relevant assetEnspryng (satralizumab; IL-6R)

Stage or statusApproved for TED

Portfolio provenanceAffiliate: Chugai

Mechanistic whitespaceYes, no TSHR asset

Overlap riskMedium-high in TED

Approach thesisTier 1 to 2. Pitch oral, Graves-first control with TED expansion, and use IL-6R as the downstream comparator rather than the central story.

Sanofi

Relevant franchiseRare immune-mediated disease

Closest relevant assetRilzabrutinib (BTK)

Stage or statusPhase 2 in Graves disease

Portfolio provenanceAcquired: Principia, $3.68B

Mechanistic whitespaceYes, no TSHR asset

Overlap riskHigh in Graves

Approach thesisTier 2, conditional. Approach only with compelling TSHR-specific differentiation, biomarker enrichment or a superior safety and response profile. Otherwise deprioritize.

Review Mode

A first pass you can put your name on

Every value has its source and a confidence score, and is marked sourced, inferred, or unknown. Sleuth checks its own work first, then Review mode shows you the few cells it couldn’t settle, and why.

See how every value gets checked
Monitoring

Next month, you start from what changed

Turn on monitoring, and Sleuth updates the data behind your analysis as trials, filings, and deals come in. You see what changed and where it came from, and can go back to any earlier version. Leave it on, and the analysis becomes a dashboard your team checks every week.

Or run Sleuth analyses from Claude, ChatGPT, or Copilot

On its own, Claude rebuilds each landscape from the open web and misses much of it. Connect Sleuth, and Claude, ChatGPT, Copilot, or other AI tools work from the same knowledge base as Studio. Every project they run is saved to your Studio account.

63%

more of the landscape found with Sleuth connected, on average across 15 tests

+55%

Claude

Alone

With Sleuth

+27%

ChatGPT

Alone

With Sleuth

+108%

Perplexity

Alone

With Sleuth

How teams use Studio

Project Deep Dive

A nine-person biotech screened 167 autoimmune indications in Studio, narrowed them to one lead basket, and refined the work in place when its board pushed back.

Power User

Juvena’s CSO covers a first-in-class pipeline in Studio, from mapping who else is working on each new target to weighing which drug formats could win.

Across Teams

Five teams at a top-10 pharma do their research in Studio, from choosing which exhibitors to meet at a partnering event to checking a partner’s asking price.

Run your first analysis in Studio

Set up in Claude, ChatGPT, or Copilot